Implanted low-inflammation subcutaneous fluid delivery port with a metered owner-operated giving set, for chronic kidney disease in cats — business case

Intended use: For placement by a licensed veterinarian to provide repeated subcutaneous administration of isotonic crystalloid fluids by the owner at home, in cats with chronic kidney disease requiring ongoing fluid therapy, as an alternative to repeated percutaneous needle sticks.

Who pays

The budget-holder chain has one cheque in it, and it is written entirely out of discretionary household spending — there is no second cheque from a payer sitting behind it, and that is a structural fact about this candidate rather than a gap in this repo's connectors.

• Writes the cheque: the cat's owner, cash-pay at the point of service [claim 7: unconfirmed]. No practice, distributor, or insurer stands between the owner and the bill in the way a DME supplier or a hospital would in a human-medicine chain.
• Out of which budget line: the owner's own veterinary spending. There is no third-party payer code of any kind for veterinary hydration therapy, and none is coming [claim 7: unconfirmed] — hcpcs, payment and coverage were deliberately not run against this candidate, for the same reason the candidate file itself gives: those connectors query CMS, which has no jurisdiction over veterinary care, and a null from any of them would be a category error dressed as a finding, not evidence about this market. Pet insurance offsets part of the bill for a minority of owners, at a rate no claim in this file quantifies [claim 7: unconfirmed], sharpened here as [assumption A3].
• Against which comparator: two things, not one. The near-universal standard of care — owner-administered needle-and-bag subcutaneous fluids at home — and a smaller existing alternative: subcutaneous fluid ports already marketed in feline practice [claim 3: unconfirmed], for which adoption returned unverifiable (quoted below). This candidate does not enter an empty comparator field; it enters one with an incumbent practice and at least one incumbent product.
• Stops buying instead: at the owner level, the recurring needle, giving set and fluid bag spend of the needle regimen — a real but modest weekly cost this file never prices. The port and its metered giving set replace that spend with an upfront implant-kit-plus- placement cost [claim 9: unconfirmed] and a recurring consumable cost [claim 9: unconfirmed], so this reads as **substitution spend inside the same owner budget line**, not additive spend created from nothing — but only if the retail price at the point of decision is at or below what the displaced supplies would have cost over a comparable period, which no claim in this file establishes [assumption A2].

The chain's weakest link is that there is only one link, and its size is unmeasured. Unlike a human-medicine device with a payer setting a ceiling, this candidate's entire revenue model rests on what one owner will pay one time plus what they will pay monthly after — and no claim in this file, and no connector this repo can reach, prices either number.

The money model

Decomposed, not asserted, down to the point where a connector could in principle check it — and in every case here, the connector answered unverifiable, which is itself the finding.

Read the largest gap first. There is no row above that resolves to a number. Every TAM component the candidate names is itself a market-unverifiable Generator assumption, and the population denominator that would anchor the whole model is contested between two claims that do not describe the same population.

The two connectors that would ordinarily carry a business case both refuse here, and the verdicts go on the page rather than being routed around:

• python3 -m connectors market 'US population of cats under veterinary management for IRIS stage 2-4 chronic kidney disease prescribed ongoing subcutaneous fluids, multiplied by a net-to-practice price of USD250-450 for the implant kit plus USD15-30 per month of consumables, at a 10-20% obtainable share of owners already doing home subcutaneous fluids and finding it unsustainable' → unverifiable — see the box below for the connector's own words.
• python3 -m connectors adoption 'Owners of a CKD cat will choose an elective subcutaneous implant under general anaesthesia over continuing needle-based home fluid administration' → unverifiable — see the box below for the connector's own words.

market verdict, verbatim: "Market-size claim (...) has no free, authoritative, machine-queryable source. Stays unconfirmed permanently unless a human attaches a licensed report and edits the claim by hand."

adoption verdict, verbatim: "Adoption/preference claim (...) asserts what clinicians, payers, or patients would do. No free, authoritative, machine-queryable source answers that — it needs primary research (interviews, survey, published preference study). ... Do NOT substitute a model's own estimate of stakeholder behaviour: a synthetic stakeholder opinion is a fabricated claim."

The connector's own suggested rescope — coverage for the comparator, procedures for volume — does not apply here and this case does not run either: coverage and procedures both query CMS, which has no jurisdiction over veterinary care, exactly as the candidate file itself already establishes for claim 7 and claim 8. A null from either would be a category error, not a finding, and is not recorded anywhere in this case as evidence.

Path to first revenue

• First dollar comes from: the first veterinary practice that buys one implant kit and one metered giving set from the manufacturer, for one paying cat-owner client — a cash device sale, not a reimbursement event [claim 7: unconfirmed]. There is no payer dollar to arrive later in this chain; the owner's cash is the whole model.
• What must exist first, each attributed:
  • Implant material qualification and sterile packaging validation, the item the candidate names as dominating cost [claim 14: unconfirmed].
  • No FDA premarket submission — on the still-unconfirmed premise that animal-only devices sit outside premarket notification and approval [claim 1: unconfirmed]. What is established is narrower: the manufacturer itself is exempt from establishment registration under 21 CFR 807.65(b) [claim 2: verified], which is a different obligation from premarket review and does not by itself confirm the review-burden premise.
  • Distribution into feline-focused and referral veterinary practices [claim 23: unconfirmed].
  • General-practice or referral veterinarians willing to place the device as a minor procedure [claim 18: unconfirmed].
  • Some FTO position, given that a live US patent on an implanted subcutaneous port is enforceable against a veterinary-labelled device exactly as against a human-use one [claim 28: unconfirmed] — the file's own frontmatter flags a live patent estate around human-use implanted ports as the boundary this candidate must stay clear of.
• Calendar to first dollar: the candidate gives one combined estimate that bundles tooling/qualification with a multi-year oncologic case series [claim 14: unconfirmed], but that case series is not a legal precondition of a first sale on the animal-only reading — the file says so explicitly. Whether a first sale is reachable materially sooner than the combined estimate is [assumption A4].
• Capital to first dollar: same bundling problem. The candidate's low-single-digit- millions figure [claim 14: unconfirmed] covers tooling, qualification, sterile-packaging validation, and the case series together. Whether the qualification-only subset needed for a first sale costs materially less is [assumption A5].
• Channel cost and calendar to place the device with a first distributor or a first direct-sales practice relationship: not established [assumption A6].
• Consumable-margin dependency for any reading of this as a recurring-revenue rather than a one-off-implant business: not established [assumption A7].

Routes

Four, laid out and not ranked. Choosing a commercial strategy is a Tier 3 act — the same class of decision as choosing what to shortlist — so this section presents options and stops.

Route A — Direct-to-practice cash-pay device sale

The model the candidate file already describes end to end: the manufacturer sells implant kits and metered giving sets to feline-focused and referral practices, which place the device and bill the cat owner cash-pay at the point of service.

• Requires: implant material qualification and sterile-packaging validation [claim 14: unconfirmed]; the registration/listing exemption already established [claim 2: verified], resting on the still-unconfirmed premise that no premarket submission is required at all [claim 1: unconfirmed]; distribution into feline/referral practices [claim 23: unconfirmed]; general-practice or referral vets willing to place it as a minor procedure [claim 18: unconfirmed].
• Costs: the combined tooling/qualification/case-series estimate [claim 14: unconfirmed], or a materially smaller first-sale-only subset of it under [assumption A4] and [assumption A5]; plus channel cost [assumption A6].
• Killed by: claim 1 resolving false — a human-attached FDA Compliance Policy Guide reading or regulatory-counsel opinion finding that animal-only devices do, after all, require premarket notification or approval. That finding moves this candidate into the Class II/510(k) cost and calendar bracket the frontmatter's second device_class entry names as the boundary any human-use claim would cross, and this route's entire cost and calendar estimate is built on staying on the near side of it.

Route B — Recurring-revenue consumables model

Price the implant kit near cost and capture ongoing revenue through the metered giving-set consumable, sold monthly for the life of the implant — the model the candidate names directly as one of its deck-surfaced assumptions.

• Requires: practices willing to sell the implant together with an ongoing consumable supply rather than a one-off kit [claim 21: unconfirmed]; the metered giving set holding up against substitution by a generic syringe and needle into the same port [claim 22: unconfirmed]; the septum withstanding the number of accesses a multi-year home regimen requires without leaking or coring [claim 25: unconfirmed].
• Costs: consumable manufacturing and distribution at a margin against the USD 15-30/month price [claim 9: unconfirmed], under [assumption A7]; plus everything Route A requires to reach a first sale at all.
• Killed by: claim 22 resolving false — if a generic syringe and needle can be substituted into the port without meaningful loss of function, the metered giving set has no exclusivity, and the recurring revenue this route depends on is not defensible against the cheapest possible substitute.

Route C — License the surface chemistry and metered dosing mechanism to an incumbent

Ship the differentiator, not a whole device company: license or OEM-integrate the low-fouling implant surface chemistry and the metered giving set into an already-marketed feline subcutaneous port, rather than launching a standalone competing product.

• Requires: the two named moat levers being patentable and reduced to practice [claim 11: unconfirmed]; a demonstrated, not merely claimed, reduction in chronic tissue reaction from the low-fouling surface relative to standard silicone [claim 24: unconfirmed]; and a willing partner — the existing marketed feline port manufacturer named in the candidate's own predicate field, or the subcutaneous ureteral bypass device manufacturer named as the closest analog [claim 6: unconfirmed] — under [assumption A8].
• Costs: no fleet, tooling, or practice-channel investment of a full device company; in their place, a regulatory-scoping and module-validation spend against the same claim 14 baseline [claim 14: unconfirmed], and no fallback revenue if the partnership does not materialise, since this route trades a device price for a royalty or transfer price set by the partner.
• Killed by: claim 24 resolving false — a feline-tissue study (or the absence of any measurable difference in an animal study that is eventually run) showing the low-fouling surface does not reduce chronic inflammatory reaction relative to standard silicone. There is nothing distinctive to license if the material claim does not hold.

Route D — Referral-hospital, case-series-first launch

Sequence the oncologic question ahead of broad commercial launch: place the device only at veterinary teaching hospitals and specialty referral centers running the prospective case series the candidate names as the thing that would actually settle sarcoma incidence, and treat that evidence as the product rather than a cost line behind it.

• Requires: a multi-year prospective feline case series with follow-up long enough to say something about tumour incidence [claim 13: unconfirmed]; an IACUC protocol and teaching-hospital timeline [claim 14: unconfirmed]; referral/specialty placement rather than the general-practice placement Route A and B assume [claim 18: unconfirmed] (read here in the opposite direction from Routes A and B).
• Costs: the full combined estimate the candidate gives, years and low-single-digit millions [claim 14: unconfirmed], with no first-sale shortcut of the kind [assumption A4]/[assumption A5] propose for the other routes, plus a specific teaching-hospital case-series cost and calendar under [assumption A9].
• Killed by: an interim finding of oncologic risk in the case series itself — a sarcoma arising at the candidate's non-interscapular implant site during follow-up, which would falsify the core design premise that site, geometry and material choice reduce the risk the one retrieved case report attributes to the interscapular incumbent port [claim 4: unconfirmed], [claim 13: unconfirmed].

Assumption register

Every assumption cited above, with what would settle it and who could run it. These have been written back to the candidate as unverified claims 40-48 — an assumption that lives only in a business case is invisible to the Verifier.

Where this case outruns the file

Every figure with no claim behind it, gathered as work items.

• The US owned pet cat population — the denominator every TAM component in the candidate file ultimately needs and no claim states, even qualitatively.
• The retail price the owner actually pays (A2) — the file gives only the net-to-practice price [claim 9: unconfirmed]; the practice markup and a separate surgical placement fee are absent entirely.
• The pet-insurance offset rate (A3) — the file asserts a partial offset for "a minority" of owners and quantifies neither the minority nor the offset.
• The split between capital/calendar to a first sale versus capital/calendar to the case-series-backed "defensible" revenue the candidate's own capital-intensity claim concedes are different numbers (A4, A5) — the file bundles them into one estimate and names the tension without resolving it.
• Distribution/channel cost and calendar (A6) — nothing in the file names a distributor, a direct-sales model, or a cost for either.
• The recurring consumable's manufacturing margin (A7) — the file prices the consumable to the practice and never to the manufacturer.
• Partner economics for a licensing route (A8) — no claim in the file addresses whether any named incumbent would integrate rather than compete.
• Teaching-hospital case-series cost and calendar specifically, as distinct from the candidate's general estimate (A9) — the file names the case series as the pacing item and gives no site-specific costing.